What Is TB-500?

Research Background

TB-500 is a synthetic peptide fragment developed from Thymosin Beta-4 (often written Tβ4), a 43-amino-acid protein that occurs naturally in almost all human and animal cells. Thymosin Beta-4 itself has a long research history, particularly in connection with wound healing and cell movement.

It's worth being precise about the distinction here: TB-500 is much shorter than the full-length protein — commonly described as a fragment of roughly 7 amino acids, covering the region of Thymosin Beta-4 responsible for its actin-binding activity, not a copy of the full molecule. It's related to, but not identical to, the full-length natural protein used in some clinical research (including a formulation studied for dry-eye conditions by a separate biopharmaceutical research programme). Research findings on full-length Thymosin Beta-4 don't automatically apply to the shorter synthetic fragment sold under the name TB-500, and the two shouldn't be treated as interchangeable when reading the literature.

Mechanism Investigated

Thymosin Beta-4 is best known in the research literature as an actin-binding protein — actin is a structural protein involved in how cells move and change shape. This property is central to why it's been studied for wound healing and tissue repair: cell migration is a necessary step in closing a wound or repairing damaged tissue.

Beyond cell migration, research has explored its role in angiogenesis (new blood vessel formation) and its apparent anti-inflammatory properties in laboratory models. Most of this mechanistic work has been done in cell cultures and animal models, describing biological pathways under controlled conditions rather than confirmed effects in a living human body.

Published Research

Thymosin Beta-4 has a broader published research base than many peptides on this site, including some human clinical research — most notably a topical formulation studied in clinical trials for dry-eye disease, developed and published by a dedicated biopharmaceutical research programme unrelated to this site. That trial work concerned a specific, regulated formulation of the full-length protein, not the synthetic TB-500 fragment discussed here.

For TB-500 specifically, the published evidence is preclinical — laboratory and animal studies examining wound healing, tendon repair, and cell migration, often discussed alongside BPC-157 in the tissue-repair research literature given their overlapping research areas. As with BPC-157, there is essentially no published human clinical trial data specific to the TB-500 fragment itself.

Limitations

The evidence base for TB-500 specifically — as distinct from the naturally occurring Thymosin Beta-4 it's derived from — is preclinical only, drawn from laboratory and animal studies. Findings from clinical research on full-length Thymosin Beta-4 formulations should not be assumed to apply to the synthetic fragment sold as TB-500. As with much early-stage peptide research, results vary between studies, and no claim is made that any laboratory or animal finding occurs in humans. Regulatory bodies have also noted that fragments of this kind have limited documented human safety data, a further reason to treat this compound as early-stage. This article describes published research, not a use recommendation of any kind.